Patient P-01566

Synthetic patientNBL-101 · Day 115 · 35–44 · F · baseline S09Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Favorable

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

47%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S09
Day 42 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 53 GI-04 recommended — GI Support Protocol GI-04
Day 54 Patient accepted — Started GI-04 in the companion
Day 62 GI symptom burden −39% vs expected — GI Support Protocol GI-04
Day 68 Tolerance state changed — Unstable → Improving
Day 70 ME-01 recommended — Monitoring Escalation ME-01
Day 71 Patient accepted — Started ME-01 in the companion
Day 74 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 42.

Primary contributors, last 14 days

Inflammatory activity+6
Treatment adherence-3
Toxicity-3
Nutritional resilience+2

What helped?

GI Support Protocol GI-04Day 53
Result: symptom burden −39%
Monitoring Escalation ME-01Day 70
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

55%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓70
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 6.1 h, below personal baseline
Autonomic recovery ↓65
- WearableResting HR 78 bpm
- Wearable3,388 steps/day
- WearableShort sleep window
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 45
Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 30/100
Drug metabolism and exposure ↑20
- BloodToxicity index 44

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.8 · butyrate capacity 30/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 47 ms
Sleep: 6.2 h
Steps: 3,840
Resting HR: 80 bpm

Daily log: GI score 38, nutritional resilience 50, adherence 52.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01365	54%	S14	SC-12	improved	49
P-01486	54%	S18	GI-04	improved	47
P-01678	53%	S14	GI-04	improved	44
P-01559	52%	S06	GI-04	improved	42
P-01438	50%	S14	GI-04	improved	56
P-01458	50%	S14	GI-04	improved	44
P-01389	49%	S14	SC-12	improved	46
P-01713	49%	S04	GI-04	improved	46
P-01556	48%	S14	GI-04	improved	44
P-01603	48%	S14	GI-04	improved	40
P-01635	48%	S02	GI-04	improved	49
P-01746	48%	S14	NP-02	improved	47